rs397517132
|
|
|
0.070 |
GeneticVariation |
BEFREE |
The aim of the correlative tumour tissue studies was to investigate the relationship between EGFR gene copy numbers, activation of the EGFR pathway, expression and mutation of E-cadherin, V600E BRAF mutation and clinical outcome of patients with gastric and OGJ cancer treated with cetuximab combined with FUFOX.
|
22152101 |
2011 |
rs397517132
|
|
|
0.070 |
GeneticVariation |
BEFREE |
The usefulness of immunohistochemistry (IHC) as a new approach for the detection of BRAF V600E in cancer patients has been recently reported.
|
23927882 |
2013 |
rs397517132
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Patients with this cancer have a high frequency (~50%) of oncogenic <i>BRAF</i> mutations, particularly BRAF V600E.
|
29387237 |
2018 |
rs397517132
|
|
|
0.070 |
GeneticVariation |
BEFREE |
We found that gene mutations for EGFR (P = .02) and ALK (P < .001) were associated with cancer diagnosis at a younger age, and a similar trend existed for ERBB2 (P = .15) and ROS1 (P = .10) but not BRAF V600E (P = .43).
|
26720421 |
2016 |
rs397517132
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Reverse Phase Proteomic Array (RPPA, MD Anderson Cell Lines Project), RNAseq (Cancer Cell Line Encyclopedia) and vemurafenib sensitivity (Cancer Therapeutic Response Portal) data for BRAF-V600E cancer cell lines were curated.
|
31672130 |
2019 |
rs397517132
|
|
|
0.070 |
GeneticVariation |
BEFREE |
The BRAF inhibitor vemurafenib has become an important treatment option for melanoma patients, the majority of whom have a BRAF(V600E) mutation driving their malignancy.
|
23074264 |
2012 |
rs397517132
|
|
|
0.070 |
GeneticVariation |
BEFREE |
In FNA biopsy samples (n=186), immunocytochemical expression of caveolin-1 and BRAF V600E mutation coincided with malignancy.
|
27818286 |
2017 |
rs1057519847
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The results of cancer tissue specimens were identical to those with existing systems (nucleic acid-locked nucleic acid PCR clamp or cycleave PCR), except for two samples that showed both exon 19 deletions and L858R.
|
22858585 |
2012 |
rs1057519847
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The purpose of this study was to clarify the relationship between the EGFR-L858R mutation and cancer cell invasion ability and to investigate the molecular mechanisms involved in the formation of MPE.
|
26338423 |
2015 |
rs1057519847
|
|
|
0.030 |
GeneticVariation |
BEFREE |
These conjugates exhibited high antiproliferative potency against a number of cancer cell lines, including the epidermal growth factor receptor (EGFR) L858R/T790M mutant cell.
|
28236592 |
2017 |
rs1057519848
|
|
|
0.030 |
GeneticVariation |
BEFREE |
These conjugates exhibited high antiproliferative potency against a number of cancer cell lines, including the epidermal growth factor receptor (EGFR) L858R/T790M mutant cell.
|
28236592 |
2017 |
rs1057519848
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The results of cancer tissue specimens were identical to those with existing systems (nucleic acid-locked nucleic acid PCR clamp or cycleave PCR), except for two samples that showed both exon 19 deletions and L858R.
|
22858585 |
2012 |
rs1057519848
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The purpose of this study was to clarify the relationship between the EGFR-L858R mutation and cancer cell invasion ability and to investigate the molecular mechanisms involved in the formation of MPE.
|
26338423 |
2015 |
rs121434568
|
|
|
0.030 |
GeneticVariation |
BEFREE |
These conjugates exhibited high antiproliferative potency against a number of cancer cell lines, including the epidermal growth factor receptor (EGFR) L858R/T790M mutant cell.
|
28236592 |
2017 |
rs121434568
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The purpose of this study was to clarify the relationship between the EGFR-L858R mutation and cancer cell invasion ability and to investigate the molecular mechanisms involved in the formation of MPE.
|
26338423 |
2015 |
rs121434568
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The results of cancer tissue specimens were identical to those with existing systems (nucleic acid-locked nucleic acid PCR clamp or cycleave PCR), except for two samples that showed both exon 19 deletions and L858R.
|
22858585 |
2012 |
rs121913444
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our studies identify T725M and L861R as rare cancer-associated mutations inasmuch as these mutations increase EGFR activity in the absence of the activating EGF ligand in cell-based assays.
|
24743239 |
2014 |
rs121913444
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Two frequent cancer-driver mutation sequences (EGFR-L861Q, NRAS-Q61K) were tested.
|
29069899 |
2017 |
rs139429793
|
|
|
0.010 |
GeneticVariation |
BEFREE |
KRAS E63K is curated in the Catalogue of Somatic Mutations in Cancer database.
|
31289513 |
2019 |
rs140516819
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Using NGS, the following mutations were detected: nonsense mutations in four tumor suppressor genes [APC R1114X (molecular argument that the cancer was a primary tumor of colon), TP53 R213X, RB1 E137X and FBWX7 R393X & S282X], mutations in three receptor tyrosine kinases (RET A919V of high transforming activity, EGFR E114K and FLT3 L601I) well known as oncogenes.
|
28730258 |
2017 |
rs35918369
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Using NGS, the following mutations were detected: nonsense mutations in four tumor suppressor genes [APC R1114X (molecular argument that the cancer was a primary tumor of colon), TP53 R213X, RB1 E137X and FBWX7 R393X & S282X], mutations in three receptor tyrosine kinases (RET A919V of high transforming activity, EGFR E114K and FLT3 L601I) well known as oncogenes.
|
28730258 |
2017 |
rs556324078
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Moreover, we showed that the D717V, G800D, G800R, L840F, G843D, S925F, R1022Q, R1032Q, and S1100F VEGFR2 mutants promote tumor growth in mice.<b>Conclusions:</b> Our study supports WES-cfDNA as a powerful platform for portraying the somatic mutation landscape of cancer and discovery of new resistance mechanisms to cancer therapies.
|
29588308 |
2018 |
rs746763556
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Among these impactful variants are rare somatic, clinically actionable variants including EGFR S645C, ARAF S214C and S214F, ERBB2 S418T, and multiple BRAF variants, demonstrating that rare mutations can be functionally important in cancer.
|
27478040 |
2016 |
rs748491031
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We detected the epidermal growth factor receptor L858R, MSH2 R929* and telomerase reverse transcriptase amplification in the lung cancer specimen; CDH1 c.1320+1G>T mutation in the gastric cancer (GC) specimen; and MLH1 c.1896+5G>A germline mutation in the lung and GC specimens by 450 cancer-related gene mutations detection using next-generation sequencing technology.
|
31207149 |
2019 |
rs767505234
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our studies identify T725M and L861R as rare cancer-associated mutations inasmuch as these mutations increase EGFR activity in the absence of the activating EGF ligand in cell-based assays.
|
24743239 |
2014 |